6 completed. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 3 | 1 | Completed 1 |
Follow ALL: new trials by email Literature Review of ALL trials Research Report on ALL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Haploidentical Donor vs mMUD in Hematological Malignancies Peripheral blood stem cells - AML, ALL | Phase 2 / Phase 3 | Completed | DKMS gemeinnützige GmbH | 98 | 2018-01-01 | 2024-08-07 |
| Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Abatacept - AML, ALL | Phase 2 | Completed | Boston Children's Hospital | 11 | 2009-11-01 | 2019-11-21 |
| Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Clofarabine in combination with IV busulfan and ATG - MDS, AML | Phase 2 | Completed | Nantes University Hospital | 30 | 2009-10-01 | 2026-09-14 |
| Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD IL-2 - Acute Lymphoblastic Leukemia, ALL | Phase 2 | Completed | Baylor College of Medicine | 25 | 2007-06-01 | 2018-05-04 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF - AML, ALL | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 25 | 2002-12-01 | 2016-07-18 |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Cyclophosphamide, fludarabine, cyclosporine - AML, ALL | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 25 | 1999-07-01 | 2017-04-06 |
Hodgkin Disease (3) · Myelodysplastic Syndromes (3) · Myeloproliferative Disorders (3) · Anemia, Aplastic (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Anemia, Refractory (1) · Blast Crisis (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Bone Marrow Diseases (4) · Hemic and Lymphatic Diseases (4) · Neoplasms by Histologic Type (4) · Anemia (3) · Hematologic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Protein Disorders (2) · Bone Marrow Failure Disorders (2)
Cyclophosphamide (2) · Cyclosporine (2) · fludarabine (2) · Abatacept (1) · Alemtuzumab (1) · Busulfan (1) · Clofarabine (1) · Granulocyte Colony-Stimulating Factor (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Interleukin-2 (1) · Methotrexate (1) · aldesleukin (1) · fludarabine phosphate (1) · sargramostim (1)
Beth Israel Deaconess Medical Center (2) · Baylor College of Medicine (1) · Boston Children's Hospital (1) · DKMS gemeinnützige GmbH (1) · Nantes University Hospital (1)
United States (3) · France (1) · Germany (1)
David E Avigan, MD (2) · David F McDermott, MD (2) · Johannes Schetelig, Prof Dr med (1) · Leslie Kean, MD, PhD (1) · Rayne Rouce, MD (1)
PMID 24047754, PMID 24573552, PMID 24951467, PMID 25852054
2015 (1)